Silymarin in treatment of non-alcoholic steatohepatitis: A randomized clinical trial

Caspian Journal of Internal Medicine

Volumn 5, Issue 1, 2014, Pages 9-12

  Solhi, Hassan ^a   Ghahremani, Ramin ^a   Kazemifar, Amir Mohammad ^b   Yazdi, Zahra Hoseini ^a  

^a ARAK UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ALT; AST; NAFLD; NASH; Silymarin; Treatment

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LIVERGOL; PLACEBO; SILYMARIN; UNCLASSIFIED DRUG;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLIC FATTY LIVER; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IRAN; LOW CARBOHYDRATE DIET; LOW FAT DIET; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; SPORT; WEIGHT REDUCTION;

EID: 84891703344     PISSN: 20086164     EISSN: 20086172     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Petta S, Muratore C, Craxi A. Non-alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis 2009; 41: 615-25.
2. Tarnoki AD, Tarnoki DL, Bata P, et al. Heritability of non-alcoholic fatty liver disease and association with abnormal vascular parameters: A twin study. Liver Int 2012; 32: 1287-93.
3. Younossi ZM, Otgonsuren M, Venkatesan C, Mishra A. In patients with Non-Alcoholic Fatty Liver Disease (NAFLD), metabolically abnormal individuals are at a higher risk for mortality while metabolically normal individuals are not. Metabolism 2013; 62: 352-60.
4. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012; 27: 1555-60.
5. Santos RD, Agewall S. Non-alcoholic fatty liver disease and cardiovascular disease. Atherosclerosis 2012; 224: 324-5.
6. Tan HH, Chang JP. Non-alcoholic fatty liver disease. Proceedings of Singapore Healthcare 2010; 19: 36-50.
7. Socha P, Horvath A, Vajro P, et al. Pharmacological interventions for nonalcoholic fatty liver disease in adults and in children: a systematic review. J Pediatr Gastroenterol Nutr 2009; 48: 587-96.
8. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-78.
9. Langmead L, Rampton DS. Review article: herbal treatment in gastrointestinal and liver disease. Aliment Pharmacol Ther 2001; 15: 1239-52.
10. Shaker E, Mahmoud H, Mnaa S. Silymarin, the antioxidant component and Silybum marianum extracts prevent liver damage. Food and Chemical Toxicology 2010; 48: 803-806.
11. Kazemifar AM, Hajaghamohammadi AA, Samimi R, et al. Hepatoprotective property of oral silymarin is comparable to n-acetyl cysteine in acetaminophen poisoning. Gastroenterol Res 2012; 5: 190-4.
12. Hajaghamohammadi AA, Ziaee A, Rafiei R. The efficacy of silymarin in decreasing transaminase activities in non-alcoholic fatty liver disease: a randomized controlled clinical trial. Hepat Mon 2008; 8: 191-5.
13. Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepat Mon 2009; 9: 265-70.
14. Hajaghamohammadi AA, Ziaee A, Oveisi S, Masroor H. Effects of metformin, pioglitazone, and silymarin treatment on non-alcoholic fatty liver disease: a randomized controlled pilot study. Hepat Mon 2012; 12: 1-6.
15. Loguercio C, Federico A, Trappoliere M, et al. The effect of a silybin-vitamin e-phospholipid complex on nonalcoholic fatty liver disease: a pilot study. Dig Dis Sci 2007; 52: 2387-95.
16. Loguercio C, Andreone P, Brisc C, et al. Silybin combined with phosphatidyl choline and vitamin E in patients with nonalcoholic fatty liver disease: A randomized controlled trial. Free Radic Biol Med 2012; 52: 1658-65.